A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer
Whang, Young E., M.D., Ph.D, Armstrong, Andrew J., M.D, Rathmell, W. Kimryn, M.D., Ph.D, Godley, Paul A., M.D., Ph.D, Kim, William Y., M.D, Pruthi, Raj S., M.D, Wallen, Eric M., M.D, Crane, Jeffrey M., M.D, Moore, Dominic T., M.P.H, Grigson, Gayle, R.N, Morris, Karla, R.N, Watkins, Catharine P., B.A, George, Daniel J., M.D
Published in Urologic oncology (2013)
Published in Urologic oncology (2013)
Get full text
Journal Article